Banque Cantonale Vaudoise’s BioXcel Therapeutics BTAI Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-156	Closed	-$51K	–	1321
2021 Q4	$51K	Hold	156	–	–	﹤0.01%	1066
2021 Q3	$76K	Hold	156	–	–	﹤0.01%	991
2021 Q2	$73K	Hold	156	–	–	﹤0.01%	1004
2021 Q1	$108K	Buy	+156	New	+$125K	0.01%	898

Other funds holding BTAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Banque Cantonale Vaudoise's BTAI Position: Q1 2022 in Review

Banque Cantonale Vaudoise sold out of BioXcel Therapeutics (BTAI) in Q1 2022, closing a stake of 156 shares — an estimated $51K sold.

Banque Cantonale Vaudoise first reported a position in BTAI in Q1 2021 and held it in 4 quarters. The position peaked at $108K in Q1 2021. 96 funds tracked by Wall St. Rank hold BTAI as of Q1 2022.

Banque Cantonale Vaudoise reported no remaining BioXcel Therapeutics position as of Q1 2022 after selling out during the quarter.
Banque Cantonale Vaudoise sold 156 BioXcel Therapeutics shares in Q1 2022, an estimated $51K.
Banque Cantonale Vaudoise first reported a position in BioXcel Therapeutics in Q1 2021 and held it in 4 quarters.
Banque Cantonale Vaudoise's BioXcel Therapeutics position peaked at $108K in Q1 2021.
96 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2022.

Based on Banque Cantonale Vaudoise's 13F filing for Q1 2022, filed 9 May 2022.